NATIONAL CANCER CENTER HOSPITAL EAST

Study on MPC patients treated with mFFX or GnP at NCCHE, focusing on survival, safety, and cost-effectiveness. Utilized a partitioned survival model to compare healthcare costs and outcomes, calculating QoL scores and direct medical costs. Sensitivity analysis assessed parameter impacts on ICER.

Zolbetuximab, a CLDN18.2-targeted IgG1 monoclonal antibody, combined with frontline chemotherapy, extended PFS and OS in HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma patients positive for CLDN18.2, according to phase 3 SPOTLIGHT and GLOW trials. The FDA approved zolbetuximab in October 2024 for first-line treatment of these patients. Median PFS was 9.2 months with zolbetuximab vs 8.2 months with placebo, and median OS was 16.4 months vs 13.7 months, respectively. Zolbetuximab was also approved in Japan and Europe in 2024.

Japan’s National Cancer Center selects Paradigm for nationwide clinical trial network, LC-SCRUM-CD, expanding LC-SCRUM-Asia’s precision medicine efforts. Collaborating with PREMIA and Paradigm, the network aims to streamline trials, increase patient access, and improve outcomes through tailored treatments.

Myriad Genetics, Inc. announced the issuance of a third patent by the USPTO, enhancing its tumor-informed, high-definition molecular residual disease (MRD) assay capabilities. The patent covers ultra-sensitive detection methods for tumor-specific mutations in circulating tumor DNA (ctDNA), supporting Myriad's efforts to establish a proprietary and differentiated MRD assay. Myriad's Precise MRD assay, developed using existing technology, aims to advance oncology care by detecting ctDNA at lower levels than current market products.

Myriad Genetics, Inc. announced the issuance of a third patent by the USPTO, enhancing its tumor-informed, high-definition molecular residual disease (MRD) assay capabilities. The patent covers ultra-sensitive detection methods for tumor-specific mutations in circulating tumor DNA (ctDNA), supporting Myriad's efforts to establish a proprietary and differentiated MRD assay. This development leverages Myriad's existing technology and platforms, aiming to advance oncology care and commercialize Precise MRD.

Takeda receives approval for FRUZAQLA, a novel targeted therapy for metastatic colorectal cancer in Japan, based on the positive results of the global Phase 3 FRESCO-2 trial.

Fruquintinib (Fruzaqla) approved in Japan for advanced or recurrent colorectal cancer after chemotherapy. Based on FRESCO-2 trial, fruquintinib showed improved progression-free and overall survival vs placebo. Common adverse effects include hypertension, asthenia, and hand-foot syndrome.